Skip to main content
KURA
NASDAQ Life Sciences

Kura Oncology Q2 Revenue Up 57% QoQ; Cash Runway Extended to Q4 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$10.05
Mkt Cap
$882.417M
52W Low
$5.52
52W High
$12.49
52W Position info
82% above low
Off High info
20% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

KURA sits 82% above its 52-week low of $5.52.

Summary

Kura Oncology reported Q2 2026 net product revenue of $9.1 million, up 57% sequentially, and extended its cash runway guidance into Q4 2027 with $519 million in cash and investments.


Key Events · Earnings and Guidance · KURA

  • KOMZIFTI Revenue Accelerates

    Q2 2026 net product revenue was $9.1 million, up 57% from Q1 2026, driven by accelerating uptake in relapsed/refractory NPM1-mutated AML.

  • Cash Runway Extended

    Cash, cash equivalents and short-term investments totaled $519.0 million as of June 30, 2026, sufficient to fund operations into Q4 2027.

  • Kyowa Kirin Milestone Potential

    Kura has received or expects $597.1 million under the Kyowa License Agreement, with up to $1.491 billion in total upfront and milestone payments possible.

  • Net Loss Widens

    Q2 2026 net loss was $68.3 million ($0.77 per share), compared to $66.1 million in Q2 2025, reflecting higher SG&A and R&D investment.


Analysis · KURA · Life Sciences

Kura Oncology's Q2 2026 10-Q shows accelerating KOMZIFTI launch momentum with net product revenue of $9.1 million, up 57% quarter-over-quarter. Total revenue reached $20.9 million, including $11.8 million in collaboration revenue from Kyowa Kirin. The company holds $519.0 million in cash and investments, which management states is sufficient to fund operations into the fourth quarter of 2027 — a meaningful extension of runway that reduces near-term financing risk. Net loss widened to $68.3 million for the quarter, driven by higher SG&A and R&D spending to support the commercial launch and clinical programs. The filing also discloses modifications to 10b5-1 trading plans by three senior officers, a routine governance item.

At the time of this filing, KURA was trading at $10.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $882.4M. The 52-week trading range was $5.52 to $12.49. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KURA - Latest Insights

KURA
Aug 12, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.12
Real-time Price: $10.17 info
Change: +$0.050 (+0.49%) info
Market Cap: $882.417M info
KURA
Jul 14, 2026, 7:02 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.45
Real-time Price: $10.17 info
Change: -$1.28 (-11%) info
Market Cap: $882.417M info
KURA
Jun 11, 2026, 8:02 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.83
Real-time Price: $10.17 info
Change: +$1.34 (+15%) info
Market Cap: $882.417M info
KURA
Jun 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.77
Real-time Price: $10.17 info
Change: +$1.40 (+16%) info
Market Cap: $882.417M info
KURA
Jun 03, 2026, 6:53 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $9.09
Real-time Price: $10.17 info
Change: +$1.08 (+12%) info
Market Cap: $882.417M info